Sana Biotechnology Taps Scorpion Veteran as CFO Amid Key Clinical Milestones — Sana Biotechnology, Inc.

Event summary

Brian Piper appointed as Executive Vice President and CFO of Sana Biotechnology, effective February 17, 2026.
Piper brings 25 years of biopharmaceutical financial experience, most recently as CFO of Scorpion Therapeutics and Antares Therapeutics.
Sana expects initial clinical data for SC451 (type 1 diabetes) and SG293 (B-cell disease) within 12-18 months.
Piper's focus includes capital allocation, operational excellence, and supporting Sana's type 1 diabetes and in vivo CAR T programs.

The big picture

Sana's appointment of Piper, a seasoned biotech CFO with M&A experience, underscores its focus on disciplined capital allocation amid a critical phase of clinical development. The move comes as the company prepares for key data readouts that could validate its engineered cell therapies and attract further investment. Piper's background in both public and private biotech firms positions him to navigate Sana's next growth stage, potentially mirroring his role in Scorpion's acquisition by Eli Lilly.

What we're watching

Clinical Milestones: The pace at which Sana delivers initial clinical data for SC451 and SG293 will determine investor confidence and potential valuation inflection points.
Capital Allocation: How Piper manages Sana's balance sheet and capital allocation amid its ambitious clinical pipeline will be critical for long-term value creation.
Operational Excellence: Whether Piper's track record in driving financial and operational excellence can be replicated at Sana, especially as it advances its type 1 diabetes and in vivo CAR T programs.